low dose Aspirin for improving fatigue of multiple sclerosis patients

assessment of effects of low dose aspirin in treatment of fatigue in patients with multiple sclerosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000353099

Acronym

nil

Enrollment

110

Registered

2010-05-04

Start date

2010-05-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Multiple sclerosis (MS) is one of disabling diseases in young’s . Fatigue is one of the most common complications of multiple sclerosis, reported in 70 to 100 percent of patients. Pathophysiology of this symptom has not fully understood in this disease, yet. Aspirin (1300mg/daily) was used for relieving this complication for the first time by Wingerchuk,D.M(2005) and reported to had statistically meaningful comparing placebo. But high dose aspirin has multiple gastrointestinal and cardiovascular complications, limiting its use. In this study low dose aspirin (80mg/daily) will be compared with placebo in treatment of fatigue in 110 MS patients in hope to reduce high dose aspirin complications.

Interventions

tablet aspirin orally 80 mg/day once a day for 8 weeks

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

-known cases of relapsing-remitting ,secondary progressive,primary progressive Multiple sclerosis -ability to walk at least 100 meters without help

Exclusion criteria

-co-existence of cardiac, respiratory, metabolic disease -exacerbation of disease in the recent month -consuming drugs affecting neurological system in 2 weeks before start point -major depression

Outcome results